Dr Reddys Laboratories (RDY) Payables (2009 - 2026)

Dr Reddys Laboratories has reported Payables for 18 years, with the latest figure at $449.4 million in Q2 2026.

• On a quarterly basis, Payables rose 2.68% year-over-year to $449.4 million in Q2 2026; TTM through Jun 2026 was $449.4 million, a 2.68% increase from a year earlier, with the FY2026 full-year figure at $456.7 million, down 47.02% from the prior year.
• Payables was $449.4 million for Q2 2026 at Dr Reddys Laboratories, up from $440.9 million in the prior quarter.
• The five-year high for Payables was $849.6 million in Q1 2025, with the low at $285.7 million in Q3 2022.
• Average Payables over 5 years is $450.2 million, with a median of $427.2 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Payables surged 114.95% in 2022, then sank 48.1% in 2026.
• Over 5 years, Payables stood at $331.4 million in 2022, then climbed by 12.74% to $373.7 million in 2023, then advanced by 14.18% to $426.6 million in 2024, then gained by 15.67% to $493.5 million in 2025, then slipped by 8.93% to $449.4 million in 2026.
• The last three Payables figures came in at $449.4 million (Q2 2026), $440.9 million (Q1 2026), and $493.5 million (Q4 2025), per Business Quant data.